Chava

Laurus Labs is a leading Indian pharmaceutical and biotechnology company specializing in active pharmaceutical ingredients (APIs), generic formulations, contract development/manufacturing services, recombinant proteins, and biotechnology. It supplies APIs to nine of the world’s top ten generic pharma companies. The company is a major supplier for anti-retroviral therapies used by one-third of HIV patients in emerging countries. It operates globally with manufacturing plants approved by major regulatory agencies including USFDA and WHO. In recent years it expanded into biotechnology through its acquisition of Richcore Lifesciences (now Laurus Bio) and investments in cell/gene therapy startups like Immunoact.